Article
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.
NAR cancer - 1 Dec 2025
Illuzzi Giuditta, Galbiati Alessandro, Staniszewska Anna D, Hanson Robert, Michaloglou Chrysiis, Cooke Sophie L, Uznańska Karolina, Białecka Maja, Solarczyk Kamil, Dev Harveer S, Massie Charlie E, Albertella Mark R, Leo Elisabetta, Forment Josep V, O'Connor Mark J
Abstract excerpt
Clinical trials show benefit of the combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) in metastatic, castration-resistant prostate cancer. While benefit was evident in patients with tumours harbouring mutations in homologous recombination repair (HRR) genes, improved outcomes were also observed in the absence of such alterations. Although there is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.